ToDAY® (cephapirin sodium intramammary infusion)

Short-duration mastitis treatment

 

Details

  • ToDAY prescription antibiotic is an intramammary mastitis treatment providing bacterial activity against Gram-positive and Gram-negative bacteria in lactating dairy cows.
  • Each 10-mL disposable, ready-to-use syringe contains the active ingredient cephapirin sodium.
  • Provides treatment against mastitis-causing pathogens including penicillin-resistant Staphylococcus aureus  and  Streptococcus agalactiae.
  • Easy two-tube treatment given 12 hours apart.
  • The Opti-Sert® tip makes partial insertion easier, allowing only a 3-mm tip to be inserted into the teat canal, reducing new infections by up to 50%.5


Presentations

  • Pail containing 144 x 10 mL syringes and 144 convenient single-use alcohol pads.
  • Cartons containing 12 x 10 mL syringes with 12 convenient single-use alcohol pads.
Features & Benefits

Proven Efficacy

Two treatments of ToDAY showed no difference in clinical and overall bacteriologic cure rates bacteriologic clinical cure rates when compared to five tubes of Spectramast® LC (ceftiofur hydrochloride).2

 

Think Positive

Intramammary mastitis treatment of Gram-positive infections is widely reported as beneficial,⁴ so those infections should be the focus of treatment.¹

 

Short Duration

Administering two syringes of ToDAY results in a short-duration milk discard of 108 hours' (4.5 days) time out-of-tank. 


Learn more about treating infection vs. inflammation (PDF).

Dosage & Administration

Presentations

  • Pail containing 144 x 10-mL syringes and 144 convenient single-use alcohol pads. 
  • Cartons containing 12 x 10-mL syringes with 12 convenient single-use alcohol pads.

Partial insertion reduces new infections

  • With the Opti-Sert® applicator tip, partial insertion reduces the incidence of new infections during the dry period.5 
  • Studies have shown that when infusing into the udder at a depth of 2 to 3 millimeters, as opposed to 5 or more millimeters, new intramammary infections can be reduced by as much as 50 percent.5

Dosage Information

  • Infuse a 10-mL syringe (200 mg cephapirin activity per syringe) after each quarter has been completely milked out. Repeat once only in 12 hours. Read and follow label directions.
Resources

Product Inserts & Labels

Technical Bulletins

Safety

Residue Warnings:

Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food. 

Treated animals must not be slaughtered for food until four days after the last treatment. 

 

Administration of more than the prescribed dose may lead to residue of antibiotic in milk longer than 96 hours.

ToDAY should be administered with caution to subjects that have demonstrated some form of allergy, particularly to penicillin. Such reactions are rare; however, should they occur, consult your veterinarian.

 

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ToDAY (cephaprin sodium) offers short duration mastitis treatment in two doses.
ToDAY (cephaprin sodium) offers short duration mastitis treatment in two doses.

Save Time, Milk and Money

Choosing a short-duration treatment protocol allows you to treat mastitis with fewer antibiotics than a five-day protocol, without sacrificing efficacy.2

Dairy cow
white background

Technical Bulletin

ToDAY Compared To Spectramast® LC

A Non-inferiority Trial Comparing a First-Generation Cephalosporin with a Third-Generation Cephalosporin in the Treatment of Non-Severe Clinical Mastitis in Dairy Cows

> Read the technical bulletin

 

References

1. Keefe G, MacDonald K, Cameron M. On-farm culture use experience and impact on antimicrobial use. University of Prince Edward Island, Charlottetown, PE, Canada.

2. Schukken YH, Zurakowski MJ, Rauch BJ, et al. Non-inferiority trial comparing a first-generation cephalosporin with a third-generation cephalosporin in the treatment of nonsevere clinical mastitis in dairy cows. J Dairy Sci 2013;96(10):6763–6774.

3. Nydam D, Virkler P, Capel M, et al. Pathogen-based treatment decisions for clinical mastitis, in Proceedings. NMC Regional Meeting 2015;1-4.

4. Hess JL, Neuder LM, Sears PM. Rethinking clinical mastitis therapy, in Proceedings. 42nd Annu Meet of the NCM 2003:372–373.

5. Sutherland SF. Novel syringe partial infusion, in Proceedings. National Mastitis Council 1989.

Trademarks

ToDAY® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. All other trademarks are the property of their respective owners. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.
US-RUM-0025-2025